{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "FlublokPI",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 1
  },
  "completeness_stats": {
    "existing_evidence": 3,
    "new_evidence_found": 1,
    "total_evidence": 4
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "5. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA. 2007 Vol. 297, pp. 1577-1582.",
      "relevance_explanation": "This reference is cited in the context of clinical studies comparing the immunogenicity of recombinant hemagglutinin (rHA) vaccines (such as Flublok, a higher-dose recombinant flu vaccine) to standard egg-based vaccines, directly supporting the claim that recombinant vaccines may induce a more robust antibody response."
    },
    {
      "id": 2,
      "quote": "3. Keitel WA, Treanor JJ, El Sahly HM, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons \u226565 years old. Vaccine 2009 Vol. 28, pp. 379-385.",
      "relevance_explanation": "This reference describes a study that directly compares the immunogenicity (antibody response) of recombinant hemagglutinin vaccines (higher-dose, non-egg-based) to standard trivalent inactivated (egg-based) vaccines in older adults, providing evidence relevant to the claim."
    },
    {
      "id": 3,
      "quote": "For the 2024-2025 influenza season it is formulated to contain 135 mcg HA per 0.5 mL dose, with 45 mcg HA of each of the following 3 influenza virus strains... Flublok contains no egg proteins, antibiotics, or preservatives.",
      "relevance_explanation": "This statement establishes that Flublok is a higher-dose recombinant flu vaccine (135 mcg total HA per dose) and is not egg-based, which is necessary context for understanding the basis of the claim regarding antibody response."
    },
    {
      "id": "comp_1",
      "quote": "2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and immunogenicity of Flublok trivalent recombinant baculovirus expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011, Vol. 29, pp. 2272-2278.",
      "relevance_explanation": "This reference describes a study that evaluated the immunogenicity of the higher-dose recombinant Flublok vaccine, which is directly relevant to the claim that it may induce a more robust antibody response than standard egg-based vaccines.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}